Christine Hicking
Frankfurter Str. 250
Darmstadt, HE 64293, Germany
Darmstadt, HE 64293, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
A First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 08, 2025
Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib.
Journal: Clinical pharmacology and therapeutics
Published: December 18, 2024
First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 10, 2023
Identification of HMGA2 as a predictive biomarker of response to bintrafusp alfa in a phase 1 trial in patients with advanced triple-negative breast cancer.
Journal: Frontiers in oncology
Published: July 06, 2022
Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis.
Journal: Multiple sclerosis and related disorders
Published: July 25, 2018
Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis.
Journal: Multiple sclerosis and related disorders
Published: July 25, 2018
Effects of Postponing Treatment in the Second Year of Cladribine Administration: Clinical Trial Simulation Analysis of Absolute Lymphocyte Counts and Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis.
Journal: Clinical pharmacokinetics
Published: July 12, 2018
Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: May 03, 2018
Cladribine tablets added to IFN-β in active relapsing MS: The ONWARD study.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: February 06, 2018
Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?
Journal: Journal of neuro-oncology
Published: June 28, 2017
Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: February 01, 2017
Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome.
Journal: Oncotarget
Published: January 03, 2016
Last Updated: 09/26/2026